Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 228 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Azithromycin Clear all
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Azithromycin Treatment for the Airway Microbiome in Asthma

NCT03736629
View directory record Official record
Conditions
Asthma Chronic
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 17, 2026, 11:56 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Combination Therapies for Gonorrhea Treatment

NCT00926796
View directory record Official record
Conditions
Gonorrhoea
Interventions
Azithromycin, Gentamicin, Gemifloxacin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
15 Years to 60 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Oct 17, 2026, 11:56 AM EDT
Completed Not applicable Interventional Results available

Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection

NCT01235546
View directory record Official record
Conditions
Endometritis, Wound Infection, Abscess, Surgical Site Infection
Interventions
Azithromycin and standard of care, Placebo and standard of care
Drug
Lead sponsor
Alan Tita
Other
Eligibility
14 Years and older · Female only
Enrollment
2,013 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
Birmingham, Alabama • New Orleans, Louisiana • Jackson, Mississippi + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Oct 17, 2026, 11:56 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Mortality Reduction After Oral Azithromycin: Mortality Study

NCT02047981
View directory record Official record
Conditions
Childhood Mortality
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Month to 60 Months
Enrollment
190,238 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
2
States / cities
San Francisco, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 17, 2026, 11:56 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Azithromycin Before Induction

NCT06543290
View directory record Official record
Conditions
Infections
Interventions
Azithromycin Pill, Placebo
Drug
Lead sponsor
Arrowhead Regional Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Colton, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 17, 2026, 11:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Under Fasting Conditions

NCT00830206
View directory record Official record
Conditions
Healthy
Interventions
Azithromycin, Zithromax®
Other · Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 17, 2026, 11:56 AM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease

NCT04553406
View directory record Official record
Conditions
Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease
Interventions
SPR720, Placebo, Open-label Standard of Care
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Altamonte Springs, Florida • Atlantis, Florida • Clearwater, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 17, 2026, 11:56 AM EDT
Completed Phase 2 Interventional

The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638)

NCT00894530
View directory record Official record
Conditions
Blepharitis
Interventions
Azithromycin ophthalmic solution, 1%, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
26
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Artesia, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2013 · Synced Oct 17, 2026, 11:56 AM EDT
Completed Not applicable Interventional

Azithromycin in the Treatment of Cryptosporidiosis in Patients Who Have Not Had Success With Other Drugs

NCT00002328
View directory record Official record
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
1 Day and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Groton, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 11:56 AM EDT
Completed No phase listed Observational

Chlamydia Trachomatis Immunology and Vaccinology Study

NCT01150747
View directory record Official record
Conditions
Chlamydia
Interventions
ceftriaxone, Azithromycin
Drug
Lead sponsor
Harold Wiesenfeld
Other
Eligibility
15 Years to 35 Years · Female only
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 17, 2026, 11:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Randomized Controlled Trial of Three Antibiotic Regimens for First Trimester Abortions

NCT02756403
View directory record Official record
Conditions
First Trimester Abortion
Interventions
Azithromycin, Doxycycline, Metronidazole, Placebo
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 17, 2026, 11:56 AM EDT
Completed Phase 2 Interventional Results available

Trial II of Lung Protection With Azithromycin in the Preterm Infant

NCT00319956
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
Hubert Ballard
Other
Eligibility
Up to 72 Hours
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 17, 2026, 11:56 AM EDT
Completed Phase 4 Interventional Results available

Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF)

NCT02677701
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
azithromycin, placebo (for azithromycin), inhaled tobramycin
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
12 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
39
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 17, 2026, 11:56 AM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 17, 2026, 11:56 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641)

NCT01220258
View directory record Official record
Conditions
Posterior Blepharoconjunctivitis
Interventions
Azithromycin ophthalmic solution, 1%
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Oct 17, 2026, 11:56 AM EDT
Completed Not applicable Interventional

An Open-Label Study of the Use of Azithromycin in Patients With Symptomatic Disseminated Mycobacterium Avium-Intracellulare Complex (MAC) Infection Failing Current Therapy

NCT00002089
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
1 Day and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Groton, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 11:56 AM EDT
Terminated Phase 2 Interventional Results available

Comparison of Two Macrolides, Azithromycin and Erythromycin, for Symptomatic Treatment of Gastroparesis

NCT01323582
View directory record Official record
Conditions
Gastroparesis
Interventions
Erythromycin, Azithromycin
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 17, 2026, 11:56 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease

NCT02960503
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Azithromycin, Placebo
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 17, 2026, 11:56 AM EDT
Suspended Phase 3 Interventional

VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)

NCT04363203
View directory record Official record
Conditions
SARS-CoV-2, COVID-19
Interventions
Hydroxychloroquine, Azithromycin, Placebo oral tablet
Drug
Lead sponsor
Salomeh Keyhani MD
Federal
Eligibility
216 Months and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Oct 17, 2026, 11:56 AM EDT
Completed Phase 3 Interventional

A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Clarithromycin Extended Release for the Treatment of Pneumonia in Adult Patients

NCT00643227
View directory record Official record
Conditions
Pneumonia
Interventions
clarithromycin extended release (ER), azithromycin SR
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
36
States / cities
Birmingham, Alabama • Haleyville, Alabama • Montgomery, Alabama + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2008 · Synced Oct 17, 2026, 11:56 AM EDT
Completed Not applicable Interventional

A Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients With Advanced HIV Infection

NCT00000895
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Nelfinavir mesylate, Nevirapine, Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 17, 2026, 11:56 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Preschool Children With Upper Respiratory Tract Illnesses Using Azythromycin and Lower Respiratory Tract Symptoms Using Oral Corticosteroids.

NCT01272635
View directory record Official record
Conditions
Asthma, Wheezing
Interventions
Azithromycin, Prednisolone, Placebo Azithromycin, Placebo Prednisolone
Drug · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
12 Months to 71 Months
Enrollment
607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
16
States / cities
Tucson, Arizona • Oakland, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Oct 17, 2026, 11:56 AM EDT
Completed Phase 4 Interventional

Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting

NCT04370782
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine, Azithromycin, Zinc Sulfate, Doxycycline
Drug
Lead sponsor
St. Francis Hospital, New York
Other
Eligibility
30 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Roslyn, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 17, 2026, 11:56 AM EDT
Completed Phase 1 Interventional

Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects.

NCT00002139
View directory record Official record
Conditions
Bacterial Infections, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 11:56 AM EDT